Literature DB >> 23676791

Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor.

Linnet Ramos1, Callum Hicks, Richard Kevin, Alex Caminer, Rajeshwar Narlawar, Michael Kassiou, Iain S McGregor.   

Abstract

The neuropeptides oxytocin (OT) and vasopressin (AVP) are recognized for their modulation of social processes in humans when delivered peripherally. However, there is surprisingly little evidence for acute social effects of peripherally administered OT or AVP in animal models. On the other hand, the party drug 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') has powerful prosocial effects in rats that appear to occur through stimulation of central OT release. Here, we directly compared the social effects of peripherally administered OT and AVP with those of MDMA, and examined a possible role for the vasopressin 1A receptor (V1AR) in the observed prosocial effects. Adult male Long-Evans rats were tested in a social interaction paradigm after OT (0.1, 0.25, 0.5, and 1 mg/kg, intraperitoneal (IP)), AVP (0.001, 0.0025, 0.005, 0.01, and 0.1 mg/kg, IP), and MDMA (2.5, 5 mg/kg, IP), or combined low doses of OT and MDMA, or AVP and MDMA. The effects of pretreatment with the non-peptide OT receptor antagonist compound 25 (C25; 5 mg/kg, IP) and the V1AR antagonist SR49059 (1 mg/kg, IP) were also examined. OT (0.5 mg/kg), AVP (0.01 mg/kg), and MDMA (5 mg/kg) potently increased 'adjacent lying', where rats meeting for the first time lie passively next to each other. C25 did not inhibit adjacent lying induced by OT, whereas SR49059 inhibited adjacent lying induced by MDMA (5 mg/kg), OT (0.5 mg/kg), and AVP (0.01 mg/kg). Interestingly, when ineffective doses of OT and MDMA, or AVP and MDMA, were combined, a robust increase in adjacent lying was observed. These results show for the first time acute prosocial effects of peripherally injected OT and AVP in laboratory rats, and suggest a commonality of action of OT, AVP, and MDMA in stimulating social behavior that involves V1ARs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23676791      PMCID: PMC3773675          DOI: 10.1038/npp.2013.125

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  73 in total

1.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

2.  A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy").

Authors:  M R Thompson; P D Callaghan; G E Hunt; J L Cornish; I S McGregor
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

3.  Oxytocin shapes the neural circuitry of trust and trust adaptation in humans.

Authors:  Thomas Baumgartner; Markus Heinrichs; Aline Vonlanthen; Urs Fischbacher; Ernst Fehr
Journal:  Neuron       Date:  2008-05-22       Impact factor: 17.173

Review 4.  Oxytocin: the great facilitator of life.

Authors:  Heon-Jin Lee; Abbe H Macbeth; Jerome H Pagani; W Scott Young
Journal:  Prog Neurobiol       Date:  2009-04-10       Impact factor: 11.685

5.  Neural correlates of MDMA ("Ecstasy")-induced social interaction in rats.

Authors:  M R Thompson; G E Hunt; I S McGregor
Journal:  Soc Neurosci       Date:  2008-05-23       Impact factor: 2.083

6.  Reduced sensitivity to MDMA-induced facilitation of social behaviour in MDMA pre-exposed rats.

Authors:  Murray R Thompson; Paul D Callaghan; Glenn E Hunt; Iain S McGregor
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-02-04       Impact factor: 5.067

Review 7.  Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Authors:  Maurice Manning; Stoytcho Stoev; Bice Chini; Thierry Durroux; Bernard Mouillac; Gilles Guillon
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

8.  A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder.

Authors:  Adam J Guastella; Alexandra L Howard; Mark R Dadds; Philip Mitchell; Dean S Carson
Journal:  Psychoneuroendocrinology       Date:  2009-02-25       Impact factor: 4.905

9.  Oxytocin protects against negative behavioral and autonomic consequences of long-term social isolation.

Authors:  Angela J Grippo; Diane M Trahanas; Robert R Zimmerman; Stephen W Porges; C Sue Carter
Journal:  Psychoneuroendocrinology       Date:  2009-06-23       Impact factor: 4.905

Review 10.  Vasopressin: behavioral roles of an "original" neuropeptide.

Authors:  Heather K Caldwell; Heon-Jin Lee; Abbe H Macbeth; W Scott Young
Journal:  Prog Neurobiol       Date:  2007-11-04       Impact factor: 11.685

View more
  50 in total

Review 1.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

2.  'Ecstasy' as a social drug: MDMA preferentially affects responses to emotional stimuli with social content.

Authors:  Margaret C Wardle; Matthew G Kirkpatrick; Harriet de Wit
Journal:  Soc Cogn Affect Neurosci       Date:  2014-03-27       Impact factor: 3.436

Review 3.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

4.  Oxytocin in the prelimbic medial prefrontal cortex reduces anxiety-like behavior in female and male rats.

Authors:  Sara Sabihi; Nicole E Durosko; Shirley M Dong; Benedetta Leuner
Journal:  Psychoneuroendocrinology       Date:  2014-03-29       Impact factor: 4.905

Review 5.  Lysergic acid diethylamide: a drug of 'use'?

Authors:  Saibal Das; Preeti Barnwal; Anand Ramasamy; Sumalya Sen; Somnath Mondal
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-23

6.  Effects of MDMA and Intranasal oxytocin on social and emotional processing.

Authors:  Matthew G Kirkpatrick; Royce Lee; Margaret C Wardle; Suma Jacob; Harriet de Wit
Journal:  Neuropsychopharmacology       Date:  2014-01-22       Impact factor: 7.853

7.  Alcohol acutely enhances decoding of positive emotions and emotional concern for positive stimuli and facilitates the viewing of sexual images.

Authors:  Patrick C Dolder; Friederike Holze; Evangelia Liakoni; Samuel Harder; Yasmin Schmid; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2016-09-19       Impact factor: 4.530

Review 8.  Oxytocin Modulation of Neural Circuits.

Authors:  Mariela Mitre; Jessica Minder; Egzona X Morina; Moses V Chao; Robert C Froemke
Journal:  Curr Top Behav Neurosci       Date:  2018

9.  WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action.

Authors:  Callum Hicks; Linnet Ramos; Tristan A Reekie; Rajeshwar Narlawar; Michael Kassiou; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

10.  Inhibition of vasopressin V1a receptors in the medioventral bed nucleus of the stria terminalis has sex- and context-specific anxiogenic effects.

Authors:  Natalia Duque-Wilckens; Michael Q Steinman; Sarah A Laredo; Rebecca Hao; Allison M Perkeybile; Karen L Bales; Brian C Trainor
Journal:  Neuropharmacology       Date:  2016-07-21       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.